Copertina

Research Communication: Serum Metabolomic Signatures Predict Tumour Recurrence After Resection or Ablation in Patients With Early‐Stage Hepatocellular Carcinoma

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Ashwini Arvind, Hiroaki Kanzaki, Fouzia Ahmed, Naoto Fujiwara, Yujin Hoshida, Amit G. Singal
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
di: Elisa Pinto, et al.
Pubblicazione: (2026)

Very Early‐Stage Detection Is Associated With Improved Survival in Patients With Unifocal Hepatocellular Carcinoma
di: Thomas Hunold, et al.
Pubblicazione: (2025)

Letter: ‘Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation’
di: You‐Jian Xu, et al.
Pubblicazione: (2024)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
di: Kuo‐Cheng Wu, et al.
Pubblicazione: (2024)

Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’
di: Dong Hyun Kim, et al.
Pubblicazione: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma
di: Sifu Yang
Pubblicazione: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
di: Zhejin Shi, et al.
Pubblicazione: (2026)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
di: Yuanyan Sun, et al.
Pubblicazione: (2026)

Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply
di: Subin Heo, et al.
Pubblicazione: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
di: Jiwon Yang, et al.
Pubblicazione: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort
di: Najib Ben Khaled, et al.
Pubblicazione: (2025)

Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma
di: Soon Sun Kim, et al.
Pubblicazione: (2025)

Editorial: Direct‐Acting Agents and Risk of Hepatocellular Carcinoma—The End of Controversy
di: Vincent Haghnejad, et al.
Pubblicazione: (2025)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
di: Daniel Q. Huang, et al.
Pubblicazione: (2026)

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma
di: Kanghee Park, et al.
Pubblicazione: (2025)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
di: Darren Jun Hao Tan, et al.
Pubblicazione: (2024)

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma
di: Rong Ding, et al.
Pubblicazione: (2026)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
di: Jia‐Ling Wu, et al.
Pubblicazione: (2025)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study
di: Ahmed Helmy
Pubblicazione: (2025)

Editorial: Tumour Burden Score and Extrahepatic Progression After TACE —Refining Risk Stratification Beyond the Liver
di: Chien‐Wei Su
Pubblicazione: (2026)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
di: Mohammad Saeid Rezaee‐Zavareh, et al.
Pubblicazione: (2026)

Editorial: Understanding the Role of the Alpha‐1 Pi* MZ Genotype in the Development of Hepatocellular Carcinoma for Patients With ACLD
di: Kaitlyn Carlson, et al.
Pubblicazione: (2026)

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)
di: Marco Sanduzzi‐Zamparelli, et al.
Pubblicazione: (2026)

Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort
di: Seogsong Jeong, et al.
Pubblicazione: (2026)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
di: Gamal Shiha, et al.
Pubblicazione: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
di: L. Aceituno, et al.
Pubblicazione: (2026)

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
di: Jonggi Choi
Pubblicazione: (2025)

PNPLA3 Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study
di: Daniel Q. Huang, et al.
Pubblicazione: (2026)

Editorial: Flipping the Script—Higher Risk of Hepatocellular Carcinoma With Tenofovir Compared to Entecavir in a French Population‐Based Cohort
di: Ariel Lee, et al.
Pubblicazione: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar?
di: Danny Con
Pubblicazione: (2025)

The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease
di: Sebastiaan ten Bokkel Huinink, et al.
Pubblicazione: (2025)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar? Authors' Reply
di: Lesley A. Patmore, et al.
Pubblicazione: (2025)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
di: Jia‐Yong Su, et al.
Pubblicazione: (2025)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
di: Isabella Lurje, et al.
Pubblicazione: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
di: Shuaibing Ying, et al.
Pubblicazione: (2026)

Editorial: Resecting Assumptions—Do Proctocolectomy Guidelines Hold Up? Author's Reply
di: Erik Lundqvist, et al.
Pubblicazione: (2025)

Letter: Using Anti‐ HBs Titres to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours
di: Tsutomu Nishida, et al.
Pubblicazione: (2026)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
di: José Luis Rueda García, et al.
Pubblicazione: (2026)